CorMedix Inc (CRMD) Stock Analysis
Verdict: WATCH (do not buy)
Post-TDAPA reimbursement reset threatens a 2027 earnings cliff, turning cheap TTM metrics into a classic biopharma cliff trap.
Investment score: 58/100
Analysis as of
Is CorMedix Inc stock worth reviewing? AI model thesis
CorMedix exhibits strong current cash generation ($86.24M Q2 2026 operating cash flow) and a $256.69M cash balance, but faces a projected 2027 earnings cliff post-TDAPA expiration. The model recommends watching for entry near key support at $6.13-$6.50.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 80/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
CorMedix Inc opportunities and risks
What speaks for CRMD
- Dialysis provider contract coverage across top-5 US operators.
What speaks against CRMD
- Post-TDAPA Medicare reimbursement cliff in 2027.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CRMD | 3.1x | 1.3x | 1.9x | 82.8% | 40.5% | 43.0% |
| LXRX | n/a | 17.7x | n/a | 98.9% | -147.4% | -10.9% |
| COLL | 14.4x | 0.9x | 3.0x | 60.0% | 5.9% | 45.9% |
| AQST | n/a | 11.2x | n/a | 67.0% | -144.6% | -7.6% |
| Peer median | n/a | 11.2x | n/a | 67.0% | -144.6% | -7.6% |
Frequently asked questions about CorMedix Inc (CRMD)
Is CRMD stock a good investment?
The cached TradeMates AI model rates CorMedix Inc as WATCH (do not buy) with an investment score of 58/100. CorMedix exhibits strong current cash generation ($86.24M Q2 2026 operating cash flow) and a $256.69M cash balance, but faces a projected 2027 earnings cliff post-TDAPA expiration. The model recommends watching for entry near key support at $6.13-$6.50. This is algorithmic model output, not personal investment advice.
Is CRMD stock a buy?
The TradeMates model verdict for CRMD is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.